Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2459075rdf:typepubmed:Citationlld:pubmed
pubmed-article:2459075lifeskim:mentionsumls-concept:C0220806lld:lifeskim
pubmed-article:2459075lifeskim:mentionsumls-concept:C0023779lld:lifeskim
pubmed-article:2459075lifeskim:mentionsumls-concept:C0001060lld:lifeskim
pubmed-article:2459075lifeskim:mentionsumls-concept:C0007009lld:lifeskim
pubmed-article:2459075lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:2459075lifeskim:mentionsumls-concept:C1444754lld:lifeskim
pubmed-article:2459075lifeskim:mentionsumls-concept:C1524075lld:lifeskim
pubmed-article:2459075lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:2459075lifeskim:mentionsumls-concept:C0221874lld:lifeskim
pubmed-article:2459075lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:2459075lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:2459075lifeskim:mentionsumls-concept:C0061293lld:lifeskim
pubmed-article:2459075lifeskim:mentionsumls-concept:C0337112lld:lifeskim
pubmed-article:2459075pubmed:issue4lld:pubmed
pubmed-article:2459075pubmed:dateCreated1988-11-15lld:pubmed
pubmed-article:2459075pubmed:abstractTextA lipid A-subunit analogue GLA-27, a 4-O-phosphono-D-glucosamine derivative carrying 3-O-tetradecanoyl and N-3-tetradecanoyloxytetradecanoyl groups, exhibited significant biological activities but no detectable pyrogenicity or local Shwarzman activity. In order to synthesize compounds combining GLA-27 with muramyl dipeptide (MDP), the OH group at the C6 position of GLA-27 was first succinylated. A compound which combined a succinylated GLA-27 (GLA-101) with 1-deoxy N-acetyl-muramyl-L-alanyl-D-isoglutamine methyl ester (1-deoxy MDP) via spacers of different carbon chain lengths of 5, 11 and 15, termed GLA-105, GLA-106 and GLA-107, respectively, and their biological activities were investigated. Intraperitoneal administration of combined preparations with spacers, GLA-105 and GLA-107, induced much higher phagocytic activity in peritoneal macrophages than GLA-27, GLA-101 and 1-deoxy MDP. The activity of GLA-106 did not increase by the combination. In induction of natural killer (NK) activity in peritoneal cells, GLA-105 and GLA-107 were significantly more active than 1-deoxy MDP but only comparable with GLA-27. GLA-101 showed stronger NK activity than GLA-27. The activity of GLA-106 was stronger than 1-deoxy MDP but weaker than GLA-27, GLA-105 and GLA-107. Mitogenic, interferon-inducing and tumor necrosis factor-inducing activities decreased by combining GLA-101 with 1-deoxy MDP. GLA-101, GLA-105 and GLA-107 strongly inhibited the formation of lesions on the tail of mice infected with Vaccinia virus. The activity was almost equivalent to that of GLA-27.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:2459075pubmed:languageenglld:pubmed
pubmed-article:2459075pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2459075pubmed:citationSubsetIMlld:pubmed
pubmed-article:2459075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2459075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2459075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2459075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2459075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2459075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2459075pubmed:statusMEDLINElld:pubmed
pubmed-article:2459075pubmed:issn0192-0561lld:pubmed
pubmed-article:2459075pubmed:authorpubmed-author:HasegawaAAlld:pubmed
pubmed-article:2459075pubmed:authorpubmed-author:YamamotoAAlld:pubmed
pubmed-article:2459075pubmed:authorpubmed-author:KissIIlld:pubmed
pubmed-article:2459075pubmed:authorpubmed-author:NishimuraCClld:pubmed
pubmed-article:2459075pubmed:authorpubmed-author:HommaJ YJYlld:pubmed
pubmed-article:2459075pubmed:authorpubmed-author:IkedaSSlld:pubmed
pubmed-article:2459075pubmed:authorpubmed-author:SakMMlld:pubmed
pubmed-article:2459075pubmed:authorpubmed-author:KumazawaYYlld:pubmed
pubmed-article:2459075pubmed:authorpubmed-author:NakatsukaMMlld:pubmed
pubmed-article:2459075pubmed:issnTypePrintlld:pubmed
pubmed-article:2459075pubmed:volume10lld:pubmed
pubmed-article:2459075pubmed:ownerNLMlld:pubmed
pubmed-article:2459075pubmed:authorsCompleteYlld:pubmed
pubmed-article:2459075pubmed:pagination339-46lld:pubmed
pubmed-article:2459075pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:meshHeadingpubmed-meshheading:2459075-...lld:pubmed
pubmed-article:2459075pubmed:year1988lld:pubmed
pubmed-article:2459075pubmed:articleTitleImmunopharmacological activities of chemically synthesized lipid A-subunit analogue GLA-27 combined with muramyl dipeptide via spacers of different carbon chain length.lld:pubmed
pubmed-article:2459075pubmed:affiliationSchool of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.lld:pubmed
pubmed-article:2459075pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2459075pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed